UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 7, 2009
NxSTAGE MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 000-51567 | | 04-3454702 |
(State or other jurisdiction of
incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
| 439 S. Union St, 5th Floor, Lawrence, MA | | 01843 |
| (Address of principal executive offices) | | (Zip Code) |
(978) 687-4700
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
International Distribution Agreement between NxStage Medical, Inc. and Kimal plc.
On May 7, 2009, NxStage Medical, Inc. (“NxStage”), entered into an International Distribution Agreement (the “Agreement”) with Kimal plc. (“Kimal”). Pursuant to the terms of the Agreement, Kimal was granted exclusive distribution rights with respect to the System One in the United Kingdom and the Republic of Ireland for five years, expiring April 30, 2014, in exchange for agreed upon minimum purchase requirements. Kimal also is granted certain distribution rights for Streamline blood tubing sets and ButtonHole needles under the Agreement. Either party may terminate the Agreement for any material breach of the Agreement by the other party if such material breach remains uncured.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
| | | | | |
| | NxStage Medical, Inc.
| |
| Date: May 7, 2009 | By: | /s/ Jeffrey H. Burbank | |
| | | Jeffrey H. Burbank | |
| | | President and Chief Executive Officer | |
| |
